×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADAP – adaptimmune therapeutics plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADAP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/16
07:42 am
adap
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/15
02:08 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
11/15
12:02 am
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/14
02:38 pm
adap
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at HC Wainwright from $4.00 to $3.50. They now have a "buy" rating on the stock.
Low
Report
Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its price target lowered by analysts at HC Wainwright from $4.00 to $3.50. They now have a "buy" rating on the stock.
11/14
12:17 pm
adap
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [Yahoo! Finance]
Medium
Report
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [Yahoo! Finance]
11/14
02:31 am
adap
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [Yahoo! Finance]
High
Report
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [Yahoo! Finance]
11/13
04:22 pm
adap
Adaptimmune Reports Q3 2024 Financial and Business Updates [Yahoo! Finance]
High
Report
Adaptimmune Reports Q3 2024 Financial and Business Updates [Yahoo! Finance]
11/7
01:55 pm
adap
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio
Medium
Report
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:05 pm
adap
adaptimmune therapeutics plc - american depositary shares
BEAT
Report
-23.3%
adaptimmune therapeutics plc - american depositary shares
Date
Time
Symbol
Headline
Impact
11/13
04:20 pm
adap
Form 10-Q Adaptimmune Therapeutics For: Sep 30
High
Report
Form 10-Q Adaptimmune Therapeutics For: Sep 30
11/13
04:11 pm
adap
Form 8-K Adaptimmune Therapeutics For: Nov 13
High
Report
Form 8-K Adaptimmune Therapeutics For: Nov 13
11/13
09:10 am
adap
Form 8-K Adaptimmune Therapeutics For: Nov 13
Medium
Report
Form 8-K Adaptimmune Therapeutics For: Nov 13
11/13
09:05 am
adap
Form SC 13G/A Adaptimmune Therapeutics Filed by: Matrix Capital Management Company, LP
Medium
Report
Form SC 13G/A Adaptimmune Therapeutics Filed by: Matrix Capital Management Company, LP
11/1
05:01 pm
adap
Form 8-K Adaptimmune Therapeutics For: Nov 01
Medium
Report
Form 8-K Adaptimmune Therapeutics For: Nov 01
9/23
04:16 pm
adap
Form 8-K Adaptimmune Therapeutics For: Sep 23
Medium
Report
Form 8-K Adaptimmune Therapeutics For: Sep 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
200.0%
11/28 Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool 23.2%
11/2 Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds [Yahoo! Finance News] 14.6%
4/29 Form 8-K Adaptimmune Therapeutics For: Apr 29 12.6%
7/3 Form 4 Adaptimmune Therapeutics For: Jul 02 Filed by: Zaks Tal Zvi 12.1%
4/1 Form 3 Adaptimmune Therapeutics For: Apr 01 Filed by: Wood Gavin 12.1%
7/22 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center 11.6%
4/13 2 Penny Stocks That Could Make You Rich [The Motley Fool] 10.1%
6/10 Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com 9.7%
9/9 United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 9.7%
11/28 Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool 23.2%
11/2 Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds [Yahoo! Finance News] 14.6%
4/29 Form 8-K Adaptimmune Therapeutics For: Apr 29 12.6%
7/3 Form 4 Adaptimmune Therapeutics For: Jul 02 Filed by: Zaks Tal Zvi 12.1%
4/1 Form 3 Adaptimmune Therapeutics For: Apr 01 Filed by: Wood Gavin 12.1%
7/22 Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center 11.6%
4/13 2 Penny Stocks That Could Make You Rich [The Motley Fool] 10.1%
6/10 Cancer Immunotherapy Markets, 2023 - ResearchAndMarkets.com 9.7%
9/9 United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 9.7%
TOP News Decliners
8/5
Form 3 Adaptimmune Therapeutics For: Aug 01 Filed by: Lunger John
-19.0%
11/6 Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update -18.6%
1/14 Form 8-K Adaptimmune Therapeutics For: Jan 13 -18.4%
5/6 Form 8-K Adaptimmune Therapeutics For: May 06 -15.1%
4/27 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) had its price target lowered by analysts at Citigroup Inc from $8.00 to $5.00. They now have a "buy" rating on the stock. -15.0%
8/1 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -14.9%
9/11 Form EFFECT Adaptimmune Therapeutics -13.4%
4/29 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -12.3%
8/1 The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis -11.1%
6/5 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
11/6 Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update -18.6%
1/14 Form 8-K Adaptimmune Therapeutics For: Jan 13 -18.4%
5/6 Form 8-K Adaptimmune Therapeutics For: May 06 -15.1%
4/27 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) had its price target lowered by analysts at Citigroup Inc from $8.00 to $5.00. They now have a "buy" rating on the stock. -15.0%
8/1 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -14.9%
9/11 Form EFFECT Adaptimmune Therapeutics -13.4%
4/29 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -12.3%
8/1 The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis -11.1%
6/5 Adaptimmune Therapeutics PLC - (NASDAQ: ADAP) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -11.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: